版本:
中国

BRIEF-Myriad Genetics announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test

June 2 Myriad Genetics Inc

* Myriad Genetics Inc announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test

* Myriad Genetics - ‍key findings are that more than 50 percent of mutations identified were in patients who would not meet current testing guidelines​

* Myriad Genetics-34 percent mutations identified in unexpected genes, confirming use of multi-gene panel testing to improve hereditary cancer-risk assessment Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐